FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

American College of Radiology to form early lung cancer detection registry

The American College of Radiology Lung Cancer Screening Registry is expanding and will evolve into the Early Lung Cancer Detection Registry in late 2025.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.

March 14, 2025

Vol.51 No.10

In Brief

IU starts mobile lung cancer screening program

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center and IU Health began a mobile lung cancer screening program, which includes a 40-foot truck with a CT scanner.

March 07, 2025

Vol.51 No.09

Clinical Roundup

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

B-cell acute lymphoblastic leukemia is a common type of ALL in adults.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.

March 07, 2025

Vol.51 No.09

Drugs & Targets

FDA approves Tevimbra + chemo for advanced ESCC

FDA approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1).

March 07, 2025

Vol.51 No.09

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

YOU MAY BE INTERESTED IN

American College of Radiology to form early lung cancer detection registry

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

IU starts mobile lung cancer screening program

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

FDA approves Tevimbra + chemo for advanced ESCC

Renew today!

Subscriber content

Never miss an issue!

Login